Table 6.

Failed clinical trials in FXS: placebo-treated effect size of improved outcome measures.

Endpoint	N	Baseline Mean Score	Baseline SD	Number of Studies	Pre-Post Correlation	Mean Score Change	Effect Size
Vineland-II Comp (<12 years)	40	68.00	46.57	2	0.7	1.71	0.04
Vineland-II Comp (<12 years) *	40	68.00	46.57	2	0.5	1.71	0.04
VAS Comp (<12 years)	33	2.18	1.47	2	0.7	1.56	1.06
VAS Comp (<12 years) *	33	2.18	1.47	2	0.5	1.54	1.05
ABC-CFX Total (>12 years)	27	44.73	28.01	2	0.7	−8.60	−0.31
ABC-CFX Total (>12 years) *	27	44.73	28.01	2	0.5	−8.60	−0.31

Abbreviations: FXS, fragile X syndrome; Vineland-II Comp, Vineland Adaptive Behavior Scale-2nd edition, Composite; VAS Comp, Visual Analog Scale, Composite; ABC-CFX Total, Aberrant Behavior Checklist-Community Total Score refactored for FXS. * Meta-analysis conducted using a pre-post correlation of 0.0 has almost identical values.